<p>abrdn Life Sciences Investors（纽约证券交易所代码：HQL - 获取免费报告）的股票在周三的午盘交易中创下了 52 周的新高。该公司的股票最高交易价格为 18.10 美元，最后交易价格为 18.1250 美元，交易量为 68327 股。该股票之前的收盘价为 17.90 美元。</p>
<h2>abrdn Life Sciences Investors 上涨 1.7%</h2>
<p>该公司的 50 日移动平均价格为 16.88 美元，200 日移动平均价格为 16.93 美元。</p>
<h2>abrdn Life Sciences Investors 增加股息</h2>
<p>该公司最近还宣布了一项季度股息，该股息于 3 月 31 日（星期二）支付。2 月 20 日（星期五）登记在册的股东获得了每股 0.56 美元的股息。这代表着每年 2.24 美元的股息和 12.3% 的收益率。该股息的除息日期为 2 月 20 日（星期五）。这比 abrdn Life Sciences Investors 之前的季度股息 0.50 美元有所增加。</p>
<h2>abrdn Life Sciences Investors 的机构交易</h2>
<p>一些机构投资者最近对 HQL 的持仓进行了调整。KPP Advisory Services LLC 在第一季度将其在 abrdn Life Sciences Investors 的股份增加了 5.8%。KPP Advisory Services LLC 现在拥有该公司 24,591 股股票，价值 40 万美元，此前在此期间又购买了 1,354 股。Geneos Wealth Management Inc.在第二季度将其在 abrdn Life Sciences Investors 的持仓增加了 200.1%。Geneos Wealth Management Inc.现在拥有该公司 2,293 股股票，价值 29,000 美元，此前在此期间又购买了 1,529 股。NewEdge Advisors LLC 在第二季度将其在 abrdn Life Sciences Investors 的股份增加了 5.2%。NewEdge Advisors LLC 现在拥有该公司 34,190 股股票，价值 438,000 美元，此前在上个季度又购买了 1,690 股。Uhlmann Price Securities LLC 在第一季度将其在 abrdn Life Sciences Investors 的股份增加了 2.3%。Uhlmann Price Securities LLC 现在拥有该公司 77,857 股股票，价值 1,267,000 美元，此前在上个季度又购买了 1,719 股。最后，Blue Bell Private Wealth Management LLC 在第三季度将其在 abrdn Life Sciences Investors 的持仓增加了 2.9%。Blue Bell Private Wealth Management LLC 现在拥有该公司 64,828 股股票，价值 1,005,000 美元，此前在此期间又购买了 1,800 股。32.21% 的股票由机构投资者和对冲基金持有。</p>
<h2>abrdn Life Sciences Investors 公司简介</h2>
<p>（获取免费报告）</p>
<p>abrdn Life Sciences Investors NYSE: HQL 是一家封闭式管理投资公司，旨在通过投资生命科学领域实现资本增值。该信托成立于 1994 年，专注于从事生物技术、制药、医疗设备、诊断及相关领域的公司的股票及相关证券。其封闭式结构使投资组合经理能够维持稳定的资本池，追求长期投资策略，并在适当时使用杠杆。</p>
<p>该基金的投资组合涵盖了公共和私人公司，重点关注推动药物开发、基因治疗、精准医疗和医疗技术创新的企业。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 abrdn Life Sciences Investors</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 abrdn Life Sciences Investors 吗？</h2>
<p>在考虑 abrdn Life Sciences Investors 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 abrdn Life Sciences Investors 并不在名单上。</p>
<p>虽然 abrdn Life Sciences Investors 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>abrdn Life Sciences Investors（纽约证券交易所代码：HQL）的股票达到了新的 52 周高点 18.10 美元，收盘价为 18.1250 美元，交易量为 68,327 股。该股票上涨了 1.7%，50 日移动平均价为 16.88 美元。公司最近将季度股息提高至每股 0.56 美元，收益率为 12.3%。机构投资者增加了持股比例，目前 32.21% 的股票由此类实体持有。该公司专注于生命科学领域的投资，包括生物技术和制药</p>

<p>Shares of abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $18.10 and last traded at $18.1250, with a volume of 68327 shares traded. The stock had previously closed at $17.90.</p>
<div class="lb-trans"><p>abrdn Life Sciences Investors（纽约证券交易所代码：HQL - 获取免费报告）的股票在周三的午盘交易中创下了 52 周的新高。该公司的股票最高交易价格为 18.10 美元，最后交易价格为 18.1250 美元，交易量为 68327 股。该股票之前的收盘价为 17.90 美元。</p>
</div><h2>abrdn Life Sciences Investors Trading Up 1.7%</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 上涨 1.7%</h2>
</div><p>The business has a fifty day moving average price of $16.88 and a 200 day moving average price of $16.93.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 16.88 美元，200 日移动平均价格为 16.93 美元。</p>
</div><h2>abrdn Life Sciences Investors Increases Dividend</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th were paid a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 12.3%. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from abrdn Life Sciences Investors's previous quarterly dividend of $0.50.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，该股息于 3 月 31 日（星期二）支付。2 月 20 日（星期五）登记在册的股东获得了每股 0.56 美元的股息。这代表着每年 2.24 美元的股息和 12.3% 的收益率。该股息的除息日期为 2 月 20 日（星期五）。这比 abrdn Life Sciences Investors 之前的季度股息 0.50 美元有所增加。</p>
</div><h2>Institutional Trading of abrdn Life Sciences Investors</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in HQL. KPP Advisory Services LLC increased its stake in shares of abrdn Life Sciences Investors by 5.8% during the first quarter. KPP Advisory Services LLC now owns 24,591 shares of the company's stock valued at $400,000 after acquiring an additional 1,354 shares during the period. Geneos Wealth Management Inc. lifted its position in abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company's stock worth $29,000 after purchasing an additional 1,529 shares during the period. NewEdge Advisors LLC boosted its stake in abrdn Life Sciences Investors by 5.2% during the 2nd quarter. NewEdge Advisors LLC now owns 34,190 shares of the company's stock valued at $438,000 after purchasing an additional 1,690 shares in the last quarter. Uhlmann Price Securities LLC boosted its stake in abrdn Life Sciences Investors by 2.3% during the 1st quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company's stock valued at $1,267,000 after purchasing an additional 1,719 shares in the last quarter. Finally, Blue Bell Private Wealth Management LLC increased its position in shares of abrdn Life Sciences Investors by 2.9% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 64,828 shares of the company's stock valued at $1,005,000 after purchasing an additional 1,800 shares during the period. 32.21% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对 HQL 的持仓进行了调整。KPP Advisory Services LLC 在第一季度将其在 abrdn Life Sciences Investors 的股份增加了 5.8%。KPP Advisory Services LLC 现在拥有该公司 24,591 股股票，价值 40 万美元，此前在此期间又购买了 1,354 股。Geneos Wealth Management Inc.在第二季度将其在 abrdn Life Sciences Investors 的持仓增加了 200.1%。Geneos Wealth Management Inc.现在拥有该公司 2,293 股股票，价值 29,000 美元，此前在此期间又购买了 1,529 股。NewEdge Advisors LLC 在第二季度将其在 abrdn Life Sciences Investors 的股份增加了 5.2%。NewEdge Advisors LLC 现在拥有该公司 34,190 股股票，价值 438,000 美元，此前在上个季度又购买了 1,690 股。Uhlmann Price Securities LLC 在第一季度将其在 abrdn Life Sciences Investors 的股份增加了 2.3%。Uhlmann Price Securities LLC 现在拥有该公司 77,857 股股票，价值 1,267,000 美元，此前在上个季度又购买了 1,719 股。最后，Blue Bell Private Wealth Management LLC 在第三季度将其在 abrdn Life Sciences Investors 的持仓增加了 2.9%。Blue Bell Private Wealth Management LLC 现在拥有该公司 64,828 股股票，价值 1,005,000 美元，此前在此期间又购买了 1,800 股。32.21% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>abrdn Life Sciences Investors Company Profile</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>abrdn Life Sciences Investors NYSE: HQL is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.</p>
<div class="lb-trans"><p>abrdn Life Sciences Investors NYSE: HQL 是一家封闭式管理投资公司，旨在通过投资生命科学领域实现资本增值。该信托成立于 1994 年，专注于从事生物技术、制药、医疗设备、诊断及相关领域的公司的股票及相关证券。其封闭式结构使投资组合经理能够维持稳定的资本池，追求长期投资策略，并在适当时使用杠杆。</p>
</div><p>The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.</p>
<div class="lb-trans"><p>该基金的投资组合涵盖了公共和私人公司，重点关注推动药物开发、基因治疗、精准医疗和医疗技术创新的企业。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than abrdn Life Sciences Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 abrdn Life Sciences Investors</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in abrdn Life Sciences Investors Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 abrdn Life Sciences Investors 吗？</h2>
</div><p>Before you consider abrdn Life Sciences Investors, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 abrdn Life Sciences Investors 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and abrdn Life Sciences Investors wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 abrdn Life Sciences Investors 并不在名单上。</p>
</div><p>While abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 abrdn Life Sciences Investors 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

abrdn Life Sciences Investors（NYSE:HQL）创下 52 周新高 - 现在是买入的好时机吗？